Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
Stanford researchers have designed a nanobody platform to selectively block a key region on T cells found within arterial plaque, with the aim of preventing thrombotic complications and myocarditis.